Want to join the conversation?
$PFE's antibody-drug conjugate (ADC) inotuzumab ozogamicin was given Breakthrough Therapy designation by FDA in acute lymphoblastic leukemia. ADC is a monoclonal antibody which binds with CD22 antigen and internalizes in cancer cells where calicheamicin is released which kills the cell. This status allows for more intensive guidance from the FDA.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?